Loading...
Market
What will be ZyVac TCV's market share in the typhoid vaccine market by 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Market research reports and industry analysis
Story
Zydus Lifesciences' ZyVac TCV Typhoid Vaccine Gets WHO Approval
Oct 23, 2024, 05:24 AM
Zydus Lifesciences Ltd announced on Wednesday that its Typhoid Vi conjugate vaccine, ZyVac TCV, has received in-principle approval from the World Health Organization (WHO). This prequalification marks a significant step for the company in addressing typhoid, a serious infectious disease. The WHO prequalification is essential for global health initiatives as it ensures the vaccine meets international standards for quality, safety, and efficacy. This approval will potentially enhance Zydus Lifesciences' market reach and contribute to global efforts in combating typhoid.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 20% • 25%
20% to 40% • 25%
41% to 60% • 25%
More than 60% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
<10% • 25%
10-20% • 25%
20-30% • 25%
>30% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%